GlassScriptPhysician profile
Wajahat H Khan
NPI 1932426905
$2,528.06
in general payments reported to CMS, 2019-2025
29 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $246 · 2021: $300 · 2022: $558 · 2023: $265 · 2024: $243 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832 · Education: $87.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.99 |
| Education | $87.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.94 | 2021-2025 | |
| Harmony Biosciences LLC | $242.98 | 2022-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $234.02 | 2020-2024 | Andexxa |
| Allergan, INC. | $216.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $209.90 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Portola Pharmaceuticals, LLC | $193.74 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $160.22 | 2020-2024 | Lifevest |
| Beone Medicines USA, INC. | $143.18 | 2025 | Tevimbra |
| Dova Pharmaceuticals | $118.81 | 2019 | |
| Inspire Medical Systems, INC. | $99.47 | 2023-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $86.63 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $57.24 | 2019-2022 | |
| Boston Scientific Corporation | $47.43 | 2021 | |
| Vapotherm INC | $46.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $38.45 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.75 | 2019-2021 | |
| Mylan Specialty L.P. | $31.34 | 2021 | |
| Tactile Systems Technology INC | $29.31 | 2025 | Flexitouch Plus, Nimbl |
| Baxter Healthcare | $27.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2025 | Aralast |
| Xeris Pharmaceuticals, INC. | $17.01 | 2024 | Keveyis |
| Pulmonx Corporation | $16.90 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Genentech USA, INC. | $15.10 | 2024 | Xolair |
| Csl Behring | $14.59 | 2019 | |
| Axsome Therapeutics, INC. | $14.57 | 2023 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.90 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.87 | 2020 | |
| Melinta Therapeutics, LLC | $12.44 | 2022 | |
| Biomerieux INC | $10.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wajahat Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.